Source: Annual Congress 2006 - Interstial lung diseases
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. Pohunek, J. Nemeckova, T. Svobodova, I. Poncakova, J. Vavrinec (Prague, Ceske Budejovice, Czech Republic). Combined immunosuppressive therapy including anti-TNFα in a treatment of severe paediatric sarcoidosis – a case report. Eur Respir J 2006; 28: Suppl. 50, 4775

Member's Comments

No comment yet.

Related content which might interest you: Standard therapy for sarcoidosis Source: Annual Congress 2005 - Biological agents in the therapy of sarcoidosis Year: 2005 Severe asthma biologic treatment in the era of COVID-19 – case series Source: Virtual Congress 2021 – Asthma and COPD meets COVID-19: new diagnostic tools and results from clinical trials Year: 2021 Therapeutic options for sarcoidosis: old and new Source: Annual Congress 2005 - PG15 - Therapeutic options for interstitial lung diseases in 2005 Year: 2005 Efficacy of traditional and combined therapy in patients with sarcoidosis Source: Eur Respir J 2003; 22: Suppl. 45, 234s Year: 2003 Super-response to dupilumab therapy in a patient with severe asthma and ABPA – a case report Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Reasons for not receiving interventional therapy in patients with severe emphysema Source: International Congress 2018 – Endoscopic lung volume reduction Year: 2018 Treatment out-come in acquired drug resistance tuberculous patients receiving tailored regimen based on sensitivity report Source: Annual Congress 2008 - Outcomes of tuberculosis treatment Year: 2008 Is there a benefit of an additive standard immunoglobulin therapy for the clinical course of COPD patients under chronic immunosuppressive therapy? Source: Eur Respir J 2001; 18: Suppl. 33, 24s Year: 2001 The course of COVID-19 in pulmonary sarcoidosis patients, receiving methotrexate Source: Virtual Congress 2021 – Moving forward in various aspects of sarcoidosis Year: 2021 Glucocorticosteroid treatment in sarcoidosis: comparison of regimens Source: Eur Respir J 2003; 22: Suppl. 45, 234s Year: 2003 Our clinical experience in surgical therapy of patients with bronchiectasis Source: Eur Respir J 2002; 20: Suppl. 38, 344s Year: 2002 Antithrombotics in idiopathic pulmonary fibrosis patients with concomitant antifibrotic therapy: a single centre real world experience Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Sarcoidosis caused by interferon therapy: case report Source: Eur Respir J 2003; 22: Suppl. 45, 233s Year: 2003 A retrospective analysis of methotrexate therapy as a steroid sparing agent within a UK severe asthma clinic Source: Annual Congress 2012 - Different ways to phenotype asthma Year: 2012 Long-term treatment with infliximab in patients with sarcoidosis Source: Annual Congress 2011 - Different profiles of sarcoidosis and other granulomatous disorders Year: 2011 Corticosteroid treatment in sarcoidosis Source: Eur Respir J 2006; 28: 627-636 Year: 2006 Follow-up of the patients with newly diagnosed sarcoidosis treated with oral corticosteroids. Features associated with chronic sarcoidosis Source: Annual Congress 2008 - Sarcoidosis and other interstitial lung diseases Year: 2008 The experience of use plasmaferesis in complex treatment in patients with pulmonary sarcoidosis (PS) Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis Year: 2008 The use of plasmapheresis in the treatment of patients with IY stage of pulmonary sarcoidosis Source: Eur Respir J 2002; 20: Suppl. 38, 434s Year: 2002 Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis Source: Eur Respir J 2014; 43: 602-609 Year: 2013